Bioceltix S.A. (BCX.WA)
PLN 119.0
(2.59%)
PLN 119.0
(2.59%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -13.68 Million PLN | -53.42% |
| 2022 | -8.92 Million PLN | -102.87% |
| 2021 | -4.39 Million PLN | -87.23% |
| 2020 | -2.34 Million PLN | -47.13% |
| 2019 | -1.59 Million PLN | -105.8% |
| 2018 | -775.69 Thousand PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.2 Million PLN | -11.7% |
| 2024 Q2 | -4.22 Million PLN | -0.54% |
| 2023 FY | -13.68 Million PLN | -53.42% |
| 2023 Q4 | -3.76 Million PLN | -6.87% |
| 2023 Q1 | -2.63 Million PLN | 6.1% |
| 2023 Q3 | -3.52 Million PLN | 6.56% |
| 2023 Q2 | -3.76 Million PLN | -43.23% |
| 2022 Q3 | -2.82 Million PLN | -51.82% |
| 2022 Q2 | -1.85 Million PLN | -29.13% |
| 2022 FY | -8.92 Million PLN | -102.87% |
| 2022 Q4 | -2.8 Million PLN | 0.66% |
| 2022 Q1 | -1.43 Million PLN | 9.22% |
| 2021 Q4 | -1.58 Million PLN | -66.09% |
| 2021 FY | -4.39 Million PLN | -87.23% |
| 2021 Q3 | -954.5 Thousand PLN | 0.0% |
| 2020 FY | -2.34 Million PLN | -47.13% |
| 2019 FY | -1.59 Million PLN | -105.8% |
| 2018 FY | -775.69 Thousand PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BIOTON S.A. | 2.27 Million PLN | 701.65% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | 80.608% |
| Mabion S.A. | 41.26 Million PLN | 133.167% |
| Molecure S.A. | -18.3 Million PLN | 25.238% |
| NanoGroup S.A. | -7.88 Million PLN | -73.484% |
| Pharmena S.A. | 28.94 Million PLN | 147.295% |
| Poltreg S.A. | -13.55 Million PLN | -1.008% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | 61.653% |
| Ryvu Therapeutics S.A. | -92.11 Million PLN | 85.14% |
| Synthaverse S.A. | 4.75 Million PLN | 387.674% |
| Urteste S.A. | -5.58 Million PLN | -145.033% |